NEW YORK, NY / ACCESSWIRE / February 3, 2017 / The Biotech Industry has experienced some steep losses in recent years, but has begun to show some signs of stabilization in 2017. The Industry was home to some impressive gains for investors from early 2013 to about the halfway mark of 2015. Over that period, the major biotech ETFs skyrocketed more than 150 percent. In comparison the S&P 500 Index posted a gain of approximately 50 percent during the same period. The iShares Nasdaq Biotechnology Index ETF and the SPDR S&P Biotech ETF have risen 5.46 percent and 10.0 percent, respectively year-to-date. The iShares Nasdaq Biotechnology Index ETF and the SPDR S&P Biotech ETF both fell approximately 40 percent from their peak in mid-July 2015 through February 2016.
Register today for a free membership and gain access to daily research reports at: RDInvesting.com
One of the biggest catalysts for impressive gains in the biotech industry has been acquisition talks. There were 326 biotech mergers & acquisitions deals completed in 2016, which were worth a total of approximately $91 billion. Experts have forecasted that number to rise in 2017 as a recent Deloitte study showed research & development productivity of 12 of the biggest biopharma companies fell to a 7-year low in 2016. Additionally, the study showed that the top 14 biopharma firms with the most cash held a total of $220 billion in cash and marketable securities at the end of the third quarter 2016.
Let's Take a Closer Look at Today's Trending Biotech Tickers
Cellect Biotechnology's shares spiked 16.52 percent to close at $4.02 a share Thursday. The stock traded between $3.56 and $5.71 on volume of 409,835 shares traded. The Company has developed a breakthrough technology for the isolation of stem cells from any given tissue, a technology that aims to improve a variety of stem cells applications. On January 12th, Cellect announced that it had received key patent from the United States Patent & Trademark Office, protecting the company's technology in multiple key indications.
Shai Yarkoni, CEO, commented that: "This is a key milestone for us and an important initial accomplishment for our business in the US. Cellect has seven families of patents and patent applications to protect its core assets for enabling stem cell regenerative medicine."
Celldex Therapeutics shares gained 4.35 percent to close at $3.36 a share Thursday. The stock traded between $3.16 and $3.45 on volume of 4.21 million shares traded. Celldex's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that the company believes "have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications." The Company's new product candidate CDX-1140 is expected to be ready to enter clinical studies in patients with advanced cancers, including lymphoma, in 2017.
"We have previously characterized CDX-1140 as possessing a needed balance between its agonist activity and its safety profile to allow for systemic dosing at levels that provide good tissue and tumor penetration, which we believe to be important in order to fully capture the benefit of CD40 immunotherapy," said Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer of Celldex Therapeutics on its December 5, 2016 press release.
Today's Features Includes:
Cellect Biotechnology Ltd. (NASDAQ: APOP)
Celldex Therapeutics, Inc. (NASDAQ: CLDX)
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.